News from boehringer ingelheim A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 23, 2015, 08:00 ET

FDA Grants Priority Review to Boehringer Ingelheim's Biologics License Application for Idarucizumab*

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the...

Apr 22, 2015, 08:00 ET

Majority of lung cancer treatment decisions are not guided by patient's genetic makeup, according to new international survey

 Despite the majority of newly diagnosed advanced non-small cell lung cancer (NSCLC) patients being tested for genetic mutations, a gap still...

Apr 06, 2015, 08:00 ET

FDA Files Supplemental New Drug Application for Boehringer Ingelheim's Pradaxa® (dabigatran etexilate mesylate) for the Prophylaxis of Deep Venous Thrombosis and Pulmonary Embolism After Hip Replacement Surgery

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) filed a supplemental New Drug...

Mar 23, 2015, 08:30 ET
Eli Lilly and Company logo

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

 Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across...

Mar 20, 2015, 13:01 ET
K. Alexander Papp, MD, PhD

Boehringer Ingelheim's Investigational Biologic Cleared Skin Better than Ustekinumab in Head-to-Head Phase II Psoriasis Study

For the first time, Boehringer Ingelheim announced Phase II data from its investigational compound BI 655066[*]. Nearly double the percentage of...

Mar 16, 2015, 08:00 ET

New Data from Boehringer Ingelheim's GLORIA™-AF Registry Show Non-Valvular Atrial Fibrillation (NVAF) Patients at High Risk of Stroke May Be Undertreated

 Boehringer Ingelheim Pharmaceuticals, Inc. today will present results from two analyses of the GLORIA™-AF Registry Program examining the...

Mar 02, 2015, 08:00 ET

Boehringer Ingelheim Submits Biologics License Application to FDA for Idarucizumab*, Investigational Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced it has submitted a biologics license application (BLA) to the U.S. Food and Drug...

Feb 21, 2015, 10:45 ET

New Phase III Data in Asthma Patients Show Tiotropium Improves Lung Function, Regardless of Allergic Status

 Boehringer Ingelheim today presented data on investigational tiotropium delivered via Respimat® inhaler from five Phase III trials from...

Feb 12, 2015, 09:19 ET

New Survey Uncovers Emotional and Physical Impact of Idiopathic Pulmonary Fibrosis, a Fatal Lung Disease

 People living with idiopathic pulmonary fibrosis (IPF) lack understanding of the disease, experience significant emotional burden and feel...

Feb 10, 2015, 13:15 ET

Boehringer Ingelheim Launches Groundbreaking Initiative "Cuida tu Don" with Entertainer "Don Francisco" Aimed at Hispanics with Type 2 Diabetes

 Today, Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) announced the launch of 'Cuida tu Don,' a national public awareness initiative...

Feb 10, 2015, 08:00 ET

Boehringer Ingelheim lanza una iniciativa innovadora "Cuida tu Don" con el animador "Don Francisco", dirigido a hispanos con diabetes tipo 2

Hoy, Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) anunció el lanzamiento de 'Cuida tu Don', una iniciativa de concientización...

Feb 02, 2015, 08:30 ET
Glyxambi® (empagliflozin/linagliptin) tablet packaging 10/5 mg (left). Glyxambi® (empagliflozin/linagliptin) tablet packaging 25/5 mg (right)

U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes

The U.S. Food and Drug Administration (FDA) has approved Glyxambi® (empagliflozin/linagliptin) tablets, from Boehringer...

Feb 02, 2015, 05:00 ET
Boehringer Ingelheim.

Leading Animal Health Company, Boehringer Ingelheim Vetmedica, Inc., Announces Website Redesign

Today, Boehringer Ingelheim Vetmedica, Inc. (BIVI), the 5th largest animal health company in the United States, announces the launch of its...

Jan 21, 2015, 09:02 ET
SPIRIVA RESPIMAT Inhalation Spray is now available by prescription through retail pharmacies across the United States for the long-term, once-daily maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema, and to reduce exacerbations in COPD patients.

SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Now Available in the United States

 Boehringer Ingelheim Pharmaceuticals, Inc. announced today that SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray is now...

Jan 12, 2015, 08:00 ET

The Lancet Oncology publishes phase III data showing Gilotrif® (afatinib) extends overall survival in lung cancer patients whose tumors have the most common EGFR mutation compared with chemotherapy

 Boehringer Ingelheim today announced overall survival (OS) results were published in The Lancet Oncology from two independent Phase III...

Dec 08, 2014, 13:30 ET

New Data Show Idarucizumab* Reverses Anticoagulant Effects of Dabigatran (PRADAXA®) in Middle-Aged, Elderly and Renally Impaired Volunteers

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced phase I data that showed administration of investigational idarucizumab in healthy...

Nov 18, 2014, 10:00 ET

New Data Show Idarucizumab* Restores Wound-Site Formation of Fibrin, a Key Component of Blood Clotting, in Healthy Volunteers Given Pradaxa® (dabigatran etexilate mesylate)

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced phase I study sub-analyses showing that its investigational antidote idarucizumab...

Nov 18, 2014, 10:00 ET

Interim Data Reinforce Safety and Effectiveness of Pradaxa® (dabigatran etexilate mesylate) versus Warfarin in Routine Care of Patients with Non-valvular Atrial Fibrillation

Brigham and Women's Hospital and Boehringer Ingelheim Pharmaceuticals, Inc. today announced interim findings from an analysis of two health...

Nov 17, 2014, 16:00 ET
Eli Lilly and Company logo.

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

Empagliflozin tablets reduced hemoglobin A1C (a measure of average blood sugar over the past two to three months), body weight and several markers...

Nov 17, 2014, 10:00 ET

U.S. Department of Defense Study Supports Favorable Benefit-Risk Profile of Pradaxa® (dabigatran etexilate mesylate) for Reducing Stroke Risk in Non-valvular Atrial Fibrillation

Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a U.S. Department of Defense cohort analysis of the Military Health System...